Terns Pharmaceuticals
Terns Pharmaceuticals, based in Foster City, California, focuses on developing small-molecule drugs for serious diseases such as oncology and obesity, with several products in clinical trials and strategic partnerships for regional developments.
Company Overview
Terns Pharmaceuticals, headquartered in Foster City, California, is dedicated to developing a portfolio of small-molecule product candidates targeting serious diseases including oncology and obesity. The company actively pursues innovative research and development to address unmet medical needs in these critical areas.
Pipeline and Clinical Trials
Terns Pharmaceuticals has a robust clinical-stage pipeline focusing on oncology and metabolic diseases. Notable developments include the initiation of a Phase 1 CARDINAL trial for TERN-701 in the United States. Received Orphan Drug Designation from the FDA for TERN-701 for the treatment of chronic myeloid leukemia. They are also conducting a Phase 1 clinical trial for TERN-601, a GLP-1R agonist aimed at treating obesity. Additionally, they presented top-line data from the Phase 2a DUET trial of TERN-501 at AASLD's The Liver Meeting.
Partnership and Licensing
Terns Pharmaceuticals has out-licensed TERN-701 to Hansoh Pharma for further development in the Greater China region. This strategic partnership aims to expedite and expand the development and commercialization of TERN-701, enabling access to one of the largest healthcare markets in the world.
FDA Designations
The FDA has granted Terns Pharmaceuticals multiple designations to facilitate the development of their innovative therapies. TERN-701 received Orphan Drug Designation for treating chronic myeloid leukemia. Additionally, TERN-501 received a Fast Track designation for the treatment of NASH, underscoring the potential impact of Terns' research in addressing pressing medical needs.
Future Plans
Looking ahead, Terns Pharmaceuticals plans to commence IND enabling studies for the TERN-800 series compounds in 2024. These compounds focus on glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity, reflecting the company's continued commitment to advancing treatment options for metabolic diseases.